Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study
Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients ho...
Guardado en:
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/52b3216a30ad4519af8484ff6cbf96f5 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:52b3216a30ad4519af8484ff6cbf96f5 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:52b3216a30ad4519af8484ff6cbf96f52021-11-25T18:07:54ZUnmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study10.3390/jpm111111922075-4426https://doaj.org/article/52b3216a30ad4519af8484ff6cbf96f52021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1192https://doaj.org/toc/2075-4426Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene–drug or gene–drug–drug interactions, were hospitalized for 9% (CI: 4–15%; <i>p</i> < 0.001) and 16% longer (CI: 8–24%; <i>p</i> < 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12–22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug–drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions.Kristine AshcraftChad MoretzChantelle SchenningSusan RojahnKae Vines TanudtanudGwyn Omar MagonciaJustine ReyesBernardo MarquezYinglong GuoElif Tokar ErdemirTaryn O. HallMDPI AGarticleCOVID-19pharmacogenomicsmedication managementhospitalizationprecision medicinelength of stayMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1192, p 1192 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
COVID-19 pharmacogenomics medication management hospitalization precision medicine length of stay Medicine R |
| spellingShingle |
COVID-19 pharmacogenomics medication management hospitalization precision medicine length of stay Medicine R Kristine Ashcraft Chad Moretz Chantelle Schenning Susan Rojahn Kae Vines Tanudtanud Gwyn Omar Magoncia Justine Reyes Bernardo Marquez Yinglong Guo Elif Tokar Erdemir Taryn O. Hall Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
| description |
Unmanaged pharmacogenomic and drug interaction risk can lengthen hospitalization and may have influenced the severe health outcomes seen in some COVID-19 patients. To determine if unmanaged pharmacogenomic and drug interaction risks were associated with longer lengths of stay (LOS) among patients hospitalized with COVID-19, we retrospectively reviewed medical and pharmacy claims from 6025 Medicare Advantage members hospitalized with COVID-19. Patients with a moderate or high pharmacogenetic interaction probability (PIP), which indicates the likelihood that testing would identify one or more clinically actionable gene–drug or gene–drug–drug interactions, were hospitalized for 9% (CI: 4–15%; <i>p</i> < 0.001) and 16% longer (CI: 8–24%; <i>p</i> < 0.001), respectively, compared to those with low PIP. Risk adjustment factor (RAF) score, a commonly used measure of disease burden, was not associated with LOS. High PIP was significantly associated with 12–22% longer LOS compared to low PIP in patients with hypertension, hyperlipidemia, diabetes, or chronic obstructive pulmonary disease (COPD). A greater drug–drug interaction risk was associated with 10% longer LOS among patients with two or three chronic conditions. Thus, unmanaged pharmacogenomic risk was associated with longer LOS in these patients and managing this risk has the potential to reduce LOS in severely ill patients, especially those with chronic conditions. |
| format |
article |
| author |
Kristine Ashcraft Chad Moretz Chantelle Schenning Susan Rojahn Kae Vines Tanudtanud Gwyn Omar Magoncia Justine Reyes Bernardo Marquez Yinglong Guo Elif Tokar Erdemir Taryn O. Hall |
| author_facet |
Kristine Ashcraft Chad Moretz Chantelle Schenning Susan Rojahn Kae Vines Tanudtanud Gwyn Omar Magoncia Justine Reyes Bernardo Marquez Yinglong Guo Elif Tokar Erdemir Taryn O. Hall |
| author_sort |
Kristine Ashcraft |
| title |
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
| title_short |
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
| title_full |
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
| title_fullStr |
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
| title_full_unstemmed |
Unmanaged Pharmacogenomic and Drug Interaction Risk Associations with Hospital Length of Stay among Medicare Advantage Members with COVID-19: A Retrospective Cohort Study |
| title_sort |
unmanaged pharmacogenomic and drug interaction risk associations with hospital length of stay among medicare advantage members with covid-19: a retrospective cohort study |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/52b3216a30ad4519af8484ff6cbf96f5 |
| work_keys_str_mv |
AT kristineashcraft unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT chadmoretz unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT chantelleschenning unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT susanrojahn unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT kaevinestanudtanud unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT gwynomarmagoncia unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT justinereyes unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT bernardomarquez unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT yinglongguo unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT eliftokarerdemir unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy AT tarynohall unmanagedpharmacogenomicanddruginteractionriskassociationswithhospitallengthofstayamongmedicareadvantagememberswithcovid19aretrospectivecohortstudy |
| _version_ |
1718411558247202816 |